Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

488 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
ICI 182,780 penetrates brain and hypothalamic tissue and has functional effects in the brain after systemic dosing.
Alfinito PD, Chen X, Atherton J, Cosmi S, Deecher DC. Alfinito PD, et al. Among authors: atherton j. Endocrinology. 2008 Oct;149(10):5219-26. doi: 10.1210/en.2008-0532. Epub 2008 Jul 3. Endocrinology. 2008. PMID: 18599545
Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.
Mutlib A, Espina R, Atherton J, Wang J, Talaat R, Scatina J, Chandrasekaran A. Mutlib A, et al. Among authors: atherton j. Chem Res Toxicol. 2012 Mar 19;25(3):572-83. doi: 10.1021/tx2005629. Epub 2012 Feb 10. Chem Res Toxicol. 2012. PMID: 22292524
Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential.
Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T, Das S. Vishwanathan K, et al. Among authors: atherton j. Drug Metab Dispos. 2014 May;42(5):932-42. doi: 10.1124/dmd.113.055335. Epub 2014 Mar 10. Drug Metab Dispos. 2014. PMID: 24616266 Clinical Trial.
A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.
Kalgutkar AS, Driscoll J, Zhao SX, Walker GS, Shepard RM, Soglia JR, Atherton J, Yu L, Mutlib AE, Munchhof MJ, Reiter LA, Jones CS, Doty JL, Trevena KA, Shaffer CL, Ripp SL. Kalgutkar AS, et al. Among authors: atherton j. Chem Res Toxicol. 2007 Dec;20(12):1954-65. doi: 10.1021/tx700270r. Epub 2007 Oct 13. Chem Res Toxicol. 2007. PMID: 17935300
Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone.
Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Feng B, Kubik R, Hanson J, Urda E, Mutlib AE. Kostrubsky SE, et al. Among authors: atherton j. Toxicol Sci. 2006 Apr;90(2):451-9. doi: 10.1093/toxsci/kfj095. Epub 2006 Jan 12. Toxicol Sci. 2006. PMID: 16410371
Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy.
Walker GS, Atherton J, Bauman J, Kohl C, Lam W, Reily M, Lou Z, Mutlib A. Walker GS, et al. Among authors: atherton j. Chem Res Toxicol. 2007 Jun;20(6):876-86. doi: 10.1021/tx600297u. Epub 2007 May 31. Chem Res Toxicol. 2007. PMID: 17536843
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Beebe JS, et al. Among authors: atherton j. Cancer Res. 2003 Nov 1;63(21):7301-9. Cancer Res. 2003. PMID: 14612527
Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies.
Mutlib A, Jiang P, Atherton J, Obert L, Kostrubsky S, Madore S, Nelson S. Mutlib A, et al. Among authors: atherton j. Chem Res Toxicol. 2006 Oct;19(10):1270-83. doi: 10.1021/tx060093j. Chem Res Toxicol. 2006. PMID: 17040096
Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites.
Mutlib A, Lam W, Atherton J, Chen H, Galatsis P, Stolle W. Mutlib A, et al. Among authors: atherton j. Rapid Commun Mass Spectrom. 2005;19(23):3482-92. doi: 10.1002/rcm.2223. Rapid Commun Mass Spectrom. 2005. PMID: 16261644
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E. Roberts WG, et al. Among authors: atherton ja. Cancer Res. 2005 Feb 1;65(3):957-66. Cancer Res. 2005. PMID: 15705896
488 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback